Lehdistötiedote

AcouSort selected for panel participation at BIO 2025

AcouSort AB (ticker: ACOU) today announced its CEO Dr. Torsten Freltoft is invited to participate in a panel discussion titled Digital, wireless, smart: Integrated care in the clinic at the international trade fair BIO 2025, which is held in Boston, MA, June 16-19. AcouSort is one of 15 companies selected by the European Innovation Council (EIC) for participation in the European Pavilion at BIO 2025.

“We are very proud - now for the fourth consecutive year - to be selected by EIC for participation at BIO 2025. This is one of the most important conferences in the healthcare and biotech industry, where most leading companies are represented and which will provide us with a great opportunity to keep extending our reach within the rapidly evolving healthcare space,” said Dr. Freltoft.

In a pitch presentation and the following panel discussion, Dr. Freltoft will present AcouSort’s innovative technology on Wednesday 18, 3-4pm EST. In the session, titled Digital, wireless, smart: Integrated care in the clinic, he will bring insights into how automated sample preparation is an important cornerstone in the healthcare future.

The delegates of the European Pavilion were selected based on their internationalization goals, technological fit with the scope of the trade fair, as well as their capacity to create business through their participation. During BIO 2025, AcouSort will also focus on partnering and 1-on-1 meetings, discussing future OEM solutions within both point-of-care diagnostics and cell therapy.

As BIO 2025 attracts 20,000+ biotechnology and pharma leaders, it offers a fantastic opportunity to identify new opportunities and promising partnerships. BIO 2025 will feature more than 100 interactive sessions across four days, covering business development, a variety of diagnostic areas as well as next generation biotherapeutics.

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is DNB Carnegie Investment Bank AB.